Key result
Concomitant COPD is linked to higher on-treatment platelet reactivity at PCI and one month later.
Observational (n=130)
Patients with COPD undergoing PCI exhibit higher on-treatment platelet reactivity, potentially contributing to their poorer post-PCI prognosis.
May warrant closer platelet reactivity monitoring in PCI patients with COPD; hypothesis-generating and should not yet change practice.
Patients with chronic obstructive pulmonary disease (COPD) show a poor prognosis after myocardial infarction (MI) and percutaneous coronary intervention (PCI). We evaluated on-treatment platelet reactivity (PR) and several gene polymorphisms related to PR in 130 patients undergoing PCI with and without COPD. Those with concomitant COPD showed higher on-treatment PR values both at the time of PCI and 1 month after. This finding may contribute to explain the poor prognosis of COPD patients after MI and PCI.
No takes yet. Share an insight, caveat, or question.
Campo et al. (2013) conducted an observational in Patients undergoing percutaneous coronary intervention with and without COPD (n=130). Concomitant chronic obstructive pulmonary disease (COPD) vs. Without COPD was evaluated on On-treatment platelet reactivity (PR) values at the time of PCI and 1 month after. In 130 patients undergoing PCI, concomitant COPD was associated with higher on-treatment platelet reactivity values both at the time of PCI and 1 month after compared to those without COPD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: